These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 38161697)
41. Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal. Isoyama S; Mori S; Sugiyama D; Kojima Y; Tada Y; Shitara K; Hinohara K; Dan S; Nishikawa H J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446575 [TBL] [Abstract][Full Text] [Related]
42. Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma. Ramamoorthi G; Kodumudi K; Snyder C; Grover P; Zhang H; Greene MI; Basu A; Gallen C; Wiener D; Costa RLB; Han HS; Koski G; Czerniecki BJ J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35710296 [TBL] [Abstract][Full Text] [Related]
43. Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells. Bae EA; Seo H; Kim BS; Choi J; Jeon I; Shin KS; Koh CH; Song B; Kim IK; Min BS; Han YD; Shin SJ; Kang CY Cancer Res; 2018 Sep; 78(18):5315-5326. PubMed ID: 30012672 [TBL] [Abstract][Full Text] [Related]
44. Interleukin 6 Present in Inflammatory Ascites from Advanced Epithelial Ovarian Cancer Patients Promotes Tumor Necrosis Factor Receptor 2-Expressing Regulatory T Cells. Kampan NC; Madondo MT; McNally OM; Stephens AN; Quinn MA; Plebanski M Front Immunol; 2017; 8():1482. PubMed ID: 29163543 [TBL] [Abstract][Full Text] [Related]
45. Amphiregulin activates regulatory T lymphocytes and suppresses CD8+ T cell-mediated anti-tumor response in hepatocellular carcinoma cells. Yuan CH; Sun XM; Zhu CL; Liu SP; Wu L; Chen H; Feng MH; Wu K; Wang FB Oncotarget; 2015 Oct; 6(31):32138-53. PubMed ID: 26451607 [TBL] [Abstract][Full Text] [Related]
46. Expression of costimulatory TNFR2 induces resistance of CD4+FoxP3- conventional T cells to suppression by CD4+FoxP3+ regulatory T cells. Chen X; Hamano R; Subleski JJ; Hurwitz AA; Howard OM; Oppenheim JJ J Immunol; 2010 Jul; 185(1):174-82. PubMed ID: 20525892 [TBL] [Abstract][Full Text] [Related]
47. Low-dose anti-VEGFR2 therapy promotes anti-tumor immunity in lung adenocarcinoma by down-regulating the expression of layilin on tumor-infiltrating CD8 Yang B; Deng B; Jiao XD; Qin BD; Lu Y; Zhang W; Guo Y; Chen S; Li D; Li B; Zang YS Cell Oncol (Dordr); 2022 Dec; 45(6):1297-1309. PubMed ID: 36260222 [TBL] [Abstract][Full Text] [Related]
48. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Li B; Lalani AS; Harding TC; Luan B; Koprivnikar K; Huan Tu G; Prell R; VanRoey MJ; Simmons AD; Jooss K Clin Cancer Res; 2006 Nov; 12(22):6808-16. PubMed ID: 17121902 [TBL] [Abstract][Full Text] [Related]
49. Abnormal generation of IL-17A represses tumor infiltration of stem-like exhausted CD8 Zhang R; Chen K; Gong C; Wu Z; Xu C; Li XN; Zhao F; Wang D; Cai J; Zhou A; Qu C BMC Med; 2023 Aug; 21(1):315. PubMed ID: 37605139 [TBL] [Abstract][Full Text] [Related]
50. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10. Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349 [TBL] [Abstract][Full Text] [Related]
51. TNFR2-expressing CD4 He J; Li R; Chen Y; Hu Y; Chen X Prog Mol Biol Transl Sci; 2019; 164():101-117. PubMed ID: 31383403 [TBL] [Abstract][Full Text] [Related]
52. Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells. Chen X; Subleski JJ; Kopf H; Howard OM; Männel DN; Oppenheim JJ J Immunol; 2008 May; 180(10):6467-71. PubMed ID: 18453563 [TBL] [Abstract][Full Text] [Related]
53. Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity. Anfray C; Mainini F; Digifico E; Maeda A; Sironi M; Erreni M; Anselmo A; Ummarino A; Gandoy S; Expósito F; Redrado M; Serrano D; Calvo A; Martens M; Bravo S; Mantovani A; Allavena P; Andón FT J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531246 [TBL] [Abstract][Full Text] [Related]
54. Pingyangmycin enhances the antitumor efficacy of anti-PD-1 therapy associated with tumor-infiltrating CD8 Shan CK; Du YB; Zhai XT; Wang YX; Li Y; Gong JH; Ge ZJ; Liu XJ; Zhen YS Cancer Chemother Pharmacol; 2021 Mar; 87(3):425-436. PubMed ID: 33388950 [TBL] [Abstract][Full Text] [Related]
55. CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity. Zammarchi F; Havenith K; Bertelli F; Vijayakrishnan B; Chivers S; van Berkel PH J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32912922 [TBL] [Abstract][Full Text] [Related]
56. Accumulation of TNFR2-expressing regulatory T cells in malignant pleural effusion of lung cancer patients is associated with poor prognosis. Ye LL; Peng WB; Niu YR; Xiang X; Wei XS; Wang ZH; Wang X; Zhang SY; Chen X; Zhou Q Ann Transl Med; 2020 Dec; 8(24):1647. PubMed ID: 33490159 [TBL] [Abstract][Full Text] [Related]
57. TNFR2 expression predicts the responses to immune checkpoint inhibitor treatments. Liao P; Jiang M; Islam MS; Wang Y; Chen X Front Immunol; 2023; 14():1097090. PubMed ID: 36865537 [TBL] [Abstract][Full Text] [Related]
58. Combination of radiotherapy and suppression of Tregs enhances abscopal antitumor effect and inhibits metastasis in rectal cancer. Ji D; Song C; Li Y; Xia J; Wu Y; Jia J; Cui X; Yu S; Gu J J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33106387 [TBL] [Abstract][Full Text] [Related]
59. Activin-A impedes the establishment of CD4 Morianos I; Tsitsopoulou A; Potaris K; Valakos D; Fari O; Vatsellas G; Bostantzoglou C; Photiades A; Gaga M; Xanthou G; Semitekolou M J Exp Clin Cancer Res; 2021 Sep; 40(1):295. PubMed ID: 34548096 [TBL] [Abstract][Full Text] [Related]